IT Security for Biotech and Life Sciences Companies in Southern California

Back to Blog

Southern California's biotech and life sciences corridor — running from San Diego's Torrey Pines cluster north through the Inland Empire and up into Los Angeles — represents one of the most valuable concentrations of intellectual property in the world. Drug pipelines worth hundreds of millions of dollars, proprietary assay platforms, clinical trial datasets, and genomic research libraries all live inside IT environments that, at many companies, were built to move fast rather than to withstand sustained adversarial pressure.

That mismatch is exactly what nation-state actors, industrial espionage operators, and ransomware groups are counting on. Biotech is not an incidental target for sophisticated threat actors — it is a deliberate one. The same qualities that make a pre-revenue biotech attractive to venture investors — a small, agile team sitting on a potentially transformative compound — also make it attractive to adversaries who understand that stealing a drug candidate costs a fraction of what discovering one does.

This guide is written for IT directors, CTOs, and operations leaders at Southern California biotech and life sciences companies. It covers the regulatory, security, and infrastructure dimensions of the problem in the order they tend to matter most — starting with why you're targeted in the first place, and ending with what to do when something goes wrong.

Why Biotech Is One of the Most Targeted Industries

The FBI and CISA have both issued explicit warnings that nation-state actors — particularly groups attributed to Chinese intelligence services, but also actors tied to Russia and Iran — actively target pharmaceutical and biotech intellectual property. This is not abstract threat intelligence. Indictments filed by the Department of Justice have named specific individuals in specific countries who were tasked with stealing research from named American biotech companies. The targets included vaccine research, oncology drug candidates, and COVID-19 treatment pipelines.

The logic driving this targeting is straightforward: developing a drug from discovery through clinical trials to FDA approval costs an average of over a billion dollars and takes more than a decade. Stealing a drug candidate — the molecular structure, the efficacy data, the manufacturing process — costs nothing but the effort of the intrusion. For a nation-state intelligence service operating at scale, biotech intellectual property offers an extraordinary return on investment.

The threat is not limited to nation-state actors. Criminal ransomware groups have also learned that biotech and life sciences companies present unusual leverage: the regulatory implications of a data breach — particularly one involving clinical trial data or patient health information — create pressure to pay ransoms that goes beyond operational disruption into regulatory exposure. A ransomware group that encrypts a clinical trial dataset and threatens to release it has found a weapon calibrated precisely to the life sciences industry.

Southern California companies are not insulated from this environment by geography or by size. Pre-clinical stage companies with fewer than fifty employees have been targeted. The relevant variable is not headcount — it is the value of what you're working on.

FDA 21 CFR Part 11: What Your IT Infrastructure Must Support

Title 21, Code of Federal Regulations, Part 11 — commonly called 21 CFR Part 11 — is the FDA regulation that governs electronic records and electronic signatures in regulated industries. If your company uses any electronic system to create, modify, maintain, archive, retrieve, or transmit records that the FDA requires to be kept, Part 11 applies to those systems.

The practical IT implications are significant. Part 11 requires that systems maintaining regulated records have audit trails that capture who made a change, what the change was, and when it occurred — and that those audit trails cannot be modified or deleted by users. It requires access controls that limit who can create or modify records. It requires that electronic signatures be linked to their signatories in a way that cannot be falsified. And it requires that records be retrievable throughout their required retention period, even as the software that created them may be updated or replaced.

For IT teams at biotech companies, this translates to a set of concrete system requirements: role-based access controls with documented authorization procedures, tamper-evident audit logging, system validation documentation demonstrating that the software does what it claims to do, and backup and recovery processes that preserve record integrity. Our team at IT Center helps life sciences clients understand which of their systems fall under Part 11 scope and what infrastructure changes are needed to bring them into alignment.

GxP IT Considerations: Validation, Audit Trails, and Data Integrity

GxP is a collective shorthand for Good Manufacturing Practice (GMP), Good Laboratory Practice (GLP), Good Clinical Practice (GCP), and related frameworks that govern quality and safety standards in pharmaceutical and biotech development. Each framework has its own regulatory home — GMP under FDA 21 CFR Parts 210/211, GLP under 21 CFR Part 58, GCP under ICH E6 — but they share a common concern for data integrity that has direct IT consequences.

Computer system validation (CSV) is the formal process of demonstrating that a software system used in a GxP environment consistently produces results that meet its intended purpose. CSV is not a one-time event — it is a lifecycle process that includes installation qualification (IQ), operational qualification (OQ), and performance qualification (PQ), followed by change control procedures that require re-validation when the system is modified. A Laboratory Information Management System (LIMS), an electronic batch record system, or a clinical data management platform used in a regulated study must go through this process.

Audit trail integrity is a non-negotiable requirement across all GxP frameworks. ALCOA+ — Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, and Available — is the data integrity standard FDA investigators apply when reviewing electronic records. Any IT environment supporting GxP activities must be designed so that audit trails cannot be disabled, backdated, or selectively deleted. This means the underlying infrastructure — operating systems, databases, network access — must also be secured against tampering by administrators who might otherwise have the technical ability to alter audit logs.

Our team is familiar with the infrastructure requirements that GxP-regulated environments demand and can help clients build systems that support validation activities, maintain data integrity controls, and preserve the audit trail chain of custody that regulators expect to see.

IP Protection: Securing Research Data in Practice

The most valuable data your company holds is probably not in your ERP system. It is in your researchers' workstations, your network file shares, your LIMS, your electronic lab notebooks, and your cloud storage drives. Securing that data requires a layered approach that addresses access controls, encryption, and behavioral monitoring in combination — because any single control, standing alone, is insufficient against a determined adversary.

Access segmentation is the foundational control. Not every researcher needs access to every project. Not every project lead needs access to the chemistry data from a different program. Role-based access controls tied to your Active Directory or identity provider — enforced at the file server, LIMS, and cloud storage levels — ensure that a compromised account in one part of the organization cannot access IP across the entire portfolio. This is not just a security principle; it is also a trade secret protection practice, because demonstrating that you took reasonable measures to restrict access is relevant to trade secret litigation.

Data loss prevention (DLP) tools can be configured to detect and block the exfiltration of specific file types — raw assay data, sequence files, clinical study reports — to unauthorized destinations, whether via email, USB, or cloud sync. This category of control is particularly relevant for biotech companies because the most damaging insider threats and sophisticated intrusions involve data that leaves the environment gradually, in ways that basic perimeter controls do not catch.

Encryption of data at rest on workstations, file servers, and portable storage should be standard practice. A researcher's laptop containing clinical trial data, stolen from a car or an airport, should produce nothing useful to a thief. Full-disk encryption achieves this at minimal operational cost.

Lab Instrument Connectivity: The IoT Problem in Your Research Environment

Modern research environments are filled with network-connected instruments: sequencers, mass spectrometers, flow cytometers, plate readers, liquid handling robots, environmental monitoring sensors. Each of these devices is, from a security perspective, an IoT device — often running an embedded operating system that is years out of date, rarely if ever patched, and connected to your primary research network with no special access restrictions.

The security implications are serious. Many lab instruments run Windows XP, Windows 7, or specialized embedded operating systems that have not received security updates for years. The manufacturers of these instruments often discourage or prohibit patching the OS, because the instrument validation depends on a specific software configuration. This creates a class of permanently vulnerable devices that must stay on your network indefinitely.

The correct response is not to patch these devices — it is to isolate them. Lab instruments should be placed on a dedicated network segment, separated from general research computing, administrative systems, and internet-facing infrastructure by firewall rules that permit only the specific communication each instrument requires. A sequencer that needs to send data to a specific LIMS server should be permitted to reach that server and nothing else. This containment strategy means that a compromised instrument cannot be used as a pivot point to reach your IP or your administrative systems.

Our managed security team regularly helps biotech clients map their instrument network, identify the devices that present the highest risk, and design the segmentation architecture that isolates them without disrupting research workflows.

Secure Collaboration with CROs and Academic Partners

Contract research organizations (CROs), academic collaborators, and clinical sites are essential to how biotech companies operate — and they represent one of the most significant sources of attack surface expansion in the industry. Every CRO you share data with is an extension of your security perimeter. If their environment is compromised, the data you shared with them is compromised, regardless of how well-secured your own network is.

The minimum viable approach to CRO and academic partner data sharing involves three elements. First, a purpose-built secure file transfer or collaboration platform — not a consumer file sync service, but a platform designed for controlled data sharing with audit trails, access expiration, and data classification enforcement. Second, a formal data sharing agreement that specifies what data will be shared, how it will be protected at the receiving organization, and what notification obligations exist if the partner experiences a security incident. Third, access provisioning that gives partners access to specific datasets for specific periods — not broad access to your network or your primary data stores.

Where remote access to systems is required — for a CRO running analyses on your LIMS data, for example — a purpose-built VPN or zero-trust access solution with multi-factor authentication and session recording is far preferable to a broadly shared remote desktop credential. Our managed IT team helps clients design the access architecture for external collaborators in a way that preserves the collaboration while limiting the security exposure.

Cloud Infrastructure for Research Computing

Cloud platforms have become central to biotech research computing: AWS, Azure, and Google Cloud all offer genomics-optimized compute environments, scalable storage for large datasets, and managed database services that can support LIMS and clinical data platforms. The scalability and cost flexibility of cloud infrastructure is genuinely compelling for research workloads that spike around specific experimental campaigns and then scale back down.

The compliance dimension of cloud adoption in a regulated environment requires careful attention, however. Data residency matters — certain regulatory frameworks require that data about individuals remain within specific geographic boundaries, and cloud configurations must enforce this. Encryption key management matters — who holds the keys to your encrypted research data in cloud storage, and what happens if your cloud provider is served with a legal demand for that data? Identity and access management in cloud environments must be configured with the same role-based discipline applied to on-premises systems, and misconfigurations in cloud IAM are among the most common sources of biotech data exposure.

For GxP-regulated workloads in the cloud, the validation obligation follows the data. Running a validated LIMS on AWS does not eliminate the CSV requirement — it changes where the infrastructure qualification documentation needs to focus. Our team is familiar with what compliant cloud configurations for regulated biotech environments look like and can help clients evaluate whether their current cloud setup meets the bar for regulatory-sensitive workloads.

SOC 2 Readiness for Biotech Companies

SOC 2 — the Service Organization Control 2 report — has become an increasingly common requirement in the biotech ecosystem. Large pharma partners, institutional investors conducting due diligence, and enterprise-scale CROs frequently ask smaller biotech companies to demonstrate SOC 2 compliance as a condition of data sharing or contract engagement. For a company that has never pursued a formal security audit, the path to SOC 2 readiness can feel opaque.

SOC 2 is built around five Trust Services Criteria: Security, Availability, Processing Integrity, Confidentiality, and Privacy. For most biotech companies seeking SOC 2 for the first time, the Security criteria — which covers logical and physical access controls, change management, risk management, and incident response — is the primary focus of a Type II audit.

• 1
  Formalize access controls and reviews. SOC 2 requires that access to systems containing sensitive data is granted based on documented authorization and reviewed on a defined schedule. Quarterly access reviews with documented evidence are a core audit expectation.
• 2
  Implement and document change management. Changes to production systems should follow a documented process with approvals, testing in a non-production environment, and rollback procedures. Ad hoc changes by individual engineers without documentation will create audit findings.
• 3
  Establish a formal vendor risk management program. SOC 2 requires that you assess the security practices of vendors who handle your data. Maintaining a vendor inventory with documented risk assessments satisfies this requirement.
• 4
  Deploy endpoint detection and centralized logging. Auditors will look for evidence that security events are captured and reviewed. An endpoint detection and response (EDR) solution feeding into centralized logging is the standard implementation.
• 5
  Document and test your incident response plan. A written IR plan with defined roles, notification procedures, and tabletop exercise history is required. Testing the plan at least annually is the expected practice.
• 6
  Establish a vulnerability management program. Regular scanning of your environment for known vulnerabilities, with a documented remediation timeline tied to severity, is a core SOC 2 security expectation.

Our team helps clients work toward SOC 2 readiness by building the underlying technical infrastructure — logging, monitoring, access management, endpoint protection — that auditors will look for, and by helping document the operational processes that turn that infrastructure into an auditable security program.

Incident Response Planning for Life Sciences

Incident response in a life sciences company is more complex than in a general business environment for two reasons: the regulatory dimension of the data involved, and the operational impact of taking systems offline that support ongoing studies. A ransomware attack that hits a general business disables operations. A ransomware attack that hits a biotech company running an ongoing clinical trial can create a regulatory documentation gap that affects the integrity of the study.

FDA breach notification considerations are specific to the data type involved. If a breach affects electronic records covered under 21 CFR Part 11 — study data, batch records, regulated laboratory data — the impact on the integrity of those records must be evaluated and documented, even if the records themselves are recovered intact. FDA investigators examining data from a clinical study may ask whether the study systems experienced any security incidents during the study period and how those incidents were documented and resolved.

If any breach involves patient health information — common in companies running clinical trials or working with biospecimens — HIPAA breach notification requirements apply. HIPAA requires notification to affected individuals within 60 days of discovering a breach, notification to HHS, and notification to prominent media outlets if more than 500 residents of a state are affected. California's CMIA adds additional state-level requirements for medical information.

The practical elements of a life sciences IR plan include a data classification map that identifies where each category of regulated data lives, pre-established relationships with outside legal counsel familiar with life sciences regulatory matters, a communication protocol for notifying regulatory bodies if study data integrity is affected, and tested backup and recovery procedures that can restore research systems to a validated state — not just a functional state — after an incident.

Containment speed matters disproportionately in biotech environments because the IP value of what an attacker can exfiltrate in an extended dwell period is so high. An adversary who has been inside a biotech network for 90 days has had ample time to copy every significant research file. Our 24/7 managed security monitoring capability is designed to detect and contain intrusions in hours rather than months — the window that makes the difference between an incident that's contained and one that results in total IP loss.

Building a Security Foundation That Matches Your Regulatory Obligations

The common thread running through every section of this guide is that biotech and life sciences companies operate under regulatory frameworks that create security obligations that go beyond what standard commercial IT practices address. 21 CFR Part 11 imposes audit trail and access control requirements. GxP frameworks impose computer system validation obligations. HIPAA imposes data protection and breach notification requirements. And the IP value of research data imposes a threat environment that would challenge much larger organizations.

Southern California has a dense concentration of biotech companies — many of them pre-revenue, operating with lean IT teams that are doing their best to keep research systems running while also trying to address a compliance and security landscape that grows more complex every year. Our team at IT Center works with life sciences clients across the region to build the IT infrastructure and security programs that match the stakes of what they're working on — from the network architecture that protects lab instruments to the cloud configurations that support validated research computing to the incident response plans that address regulated data types specifically.

If you are an IT director, CTO, or operations leader at a Southern California biotech or life sciences company and you have questions about whether your current IT environment is positioned correctly for the regulatory and security demands your organization faces, that conversation is worth having before a regulatory inspection or a security incident forces it.